ElectroCore (ECOR) Q1 2026 Earnings Transcript

Why It Matters

The results demonstrate electroCore’s ability to scale high‑margin vagus‑nerve‑stimulation products in government channels while moving toward profitability, positioning it to capture a growing non‑opioid pain‑management market.

Key Takeaways

• Q1 revenue $9.6M, up 43% YoY, record high
• Gross margin hit 87%, +200 bps YoY
• VA prescription revenue $7.9M, 48% growth; 15k patients treated
• Consumer wellness TruVega $1.5M, 38% YoY increase
• Adjusted EBITDA loss $2.3M, improved 24% YoY

Pulse Analysis

ElectroCore’s Q1 performance underscores the accelerating demand for non‑invasive vagus nerve stimulation (nVNS) within the U.S. federal health system. The VA channel alone generated $7.9 million, a 48% jump, as the company now serves roughly 15,000 veterans—still a fraction of the estimated 600,000‑plus eligible patients. This penetration is bolstered by compelling clinical data linking migraine, chronic pain, and PTSD among veterans, creating a sizable, government‑backed revenue pipeline that could expand rapidly as adoption deepens across VA facilities and into the Department of Defense.

On the consumer side, electroCore’s TruVega device posted $1.5 million in revenue, up 38% year‑over‑year, reflecting broader market trends toward drug‑free pain relief. The CDC reports that 24.3% of U.S. adults experienced chronic pain in 2023, fueling a low‑double‑digit CAGR for the global nVNS segment through 2030. By leveraging affiliate and influencer partnerships, electroCore achieved a 2.37 ROAS, indicating efficient customer acquisition and a scalable direct‑to‑consumer model that can complement its institutional sales.

Looking ahead, the company’s path to profitability hinges on translating top‑line growth into bottom‑line earnings. Operating leverage is evident as gross margin climbs to 87% while SG&A costs remain disciplined, aside from a $1.9 million transition expense. Upcoming catalysts include deeper VA and DoD channel expansion, the rollout of TACSTIM for cognitive performance, and the international soft‑launch of TruVega in the U.K. Successful execution of these initiatives could narrow the adjusted EBITDA loss further and set the stage for sustained, margin‑rich growth.